Ths study was completed last month. i found it quite interesting. These men were treat with
clomid only for their hypogonadism and were folled up on over a period of 6 months to over 3 years. it seems that
clomid may indeed be a possible treatment for hypogonadism if you can tolerate the side effects. The men were given 50mg EOD.
ANyone have any thoughts on this?
I am thinking it would be a superior form of treatment due to keeping the HPTA intact. Also on average mens sexual function on Clomid was somewhat better than it was before treatment.
Clomiphene Citrate and
Testosterone Gel Replacement Therapy for Male Hypogonadism: Efficacy and Treatment Cost
Frederick Taylor, MD, and Laurence Levine, MD
Rush University Medical Center—Department of Urology, Chicago, IL, USA
Correspondence to Frederick Taylor, MD, Urology, Rush University Medical Center, 1725 W. Congress Parkway, Suite 348, Chicago, IL 60612, USA. Tel: +312-942-6447; Fax: +312-942-4005; E-mail:
frederick_taylor@rush.edu
Copyright © 2009 International Society for Sexual Medicine
KEYWORDS
Hypogonadism • Selective Estrogen Receptor Modulator • Testosterone • Testosterone Deficiency Syndrome • Male
ABSTRACT
Introduction. The efficacy of oral clomiphene citrate (CC) in the treatment of male hypogonadism and male infertility (MI) with low serum
testosterone and normal gonadotropin levels has been reported.
Aim. The aim of this article is to evaluate CC and testosterone gel replacement therapy (TGRT) with regard to biochemical and clinical efficacy and cost.
Main Outcome Measures. The main outcome measures were change in serum testosterone with CC and TGRT therapy, and change in the androgen deficiency in aging male (ADAM) questionnaire scores with CC therapy.
Methods. Men receiving CC or TGRT with either
Androgel® 1% or Testim® 1% for hypogonadism (defined as testosterone < 300 ng/mL) or MI were included. Serum values were collected 1–2 months after treatment initiation and semi-annually thereafter. Retrospective data collection was performed via chart review. Subjective follow up of patients receiving CC was performed via telephone interview using the ADAM questionnaire.
Results. A hundred and four men (65 CC and 39 TGRT) were identified who began CC (50 mg every other day) or TGRT (5 g). Average age (years) was 42(CC) vs. 57 (TGRT). Average follow up was 23 months (CC, range 8–40 months) vs. 46 months (TGRT, range 6–149 months). Average posttreatment testosterone was 573 ng/dL in the CC group and 553 ng/dL in the TGRT group (P value < 0.001). The monthly cost of Testim® 1% (5 gm daily) is $270, Androgel® 1% (5 gm daily) is $265, and CC (50 mg every other day) is $83. Among CC patients, the average pretreatment ADAM score was 4.9 vs. 2.1 at follow up (P < 0.05). Average pretreatment ADAM sexual function domain score was 0.76 vs. 0.23 at follow up (P < 0.05). There were no adverse events reported.
Conclusion. CC represents a treatment option for men with hypogonadism, demonstrating biochemical and clinical efficacy with few side effects and lower cost as compared with TGRT. Taylor F, and Levine L. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: Efficacy and treatment cost. J Sex Med **;**:**–**.
Clomid for TRT? 
Linear Mode
